Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT06371781 |
| Other study ID # |
Cumhuriyetobgyn |
| Secondary ID |
1919B012108892 |
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
July 1, 2022 |
| Est. completion date |
July 1, 2023 |
Study information
| Verified date |
April 2024 |
| Source |
Cumhuriyet University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Researchers thought that the molecules Sfrp-5, Resistin and Netrin-4, which will be examine,
they may have a significant effect on weight gain during pregnancy. Based on these
foundations, researchers expect changes in the levels of these molecules in women who gain
excessive weight during pregnancy. In this study, researchers aimed to examine the moderator
relationship between the molecules will be examine and weight gain in women who gained weight
above the normal limits determined during pregnancy. For this reason, 44 participant who
gained excessive weight during pregnancy and 46 pregnant participant who gained normal weight
were included in the study. The levels of Netrin-4, Sfrp-5 and Resistin molecules in the
blood serum of the individuals in the study group were measured with a Commercial Elisa kit.
Description:
In this study, researchers aimed to examine the moderator relationship between molecules such
as Netrin-4, Sfrp-5 and Resistin and weight gain in participant with weight gain above the
normal limits determined during pregnancy.
Pregnant participants who were given birth at Cumhuriyet University Faculty of Medicine
Hospital Gynecology and Obstetrics Clinic between July 1, 2021 and July 1, 2022 and whose
pregnancy follow-ups were performed in our hospital were included in this prospectively
designed study. This study was divided into two main groups, the first group will consist of
pregnant participant with above-normal weight gain during pregnancy (n = 44), and the other
group will consist of pregnant participant with normal weight gain during pregnancy (n = 46).
In the study, individuals who agreed to participate in the study were first asked to fill out
a form containing demographic data such as age, education, pre- and postnatal height, and
weight.
To ensure consistency in women's care, these new Institute of Medicine (IOM) 2009 guidelines
are based on BMI cutoffs developed by the World Health Organization and adopted by the
National Heart, Lung, and Blood Institute. Weight distribution according to BMI ranges: <18.5
kg/m2 (underweight), 18.5-24.9 kg/m2 (normal weight), 25-29.9 kg/m2 (overweight) and ≥30
kg/m2 (obese). According to these guidelines, the recommended weight gain range for
underweight (UW) women is 12.5-18 kg, for normal weight (NW) women 11.5-16 kg and overweight
women (OW) 7-11.5 kg, obese ( OB) women are recommended to gain only 5-9 kg during pregnancy.
These values according to the IOM-2009 guideline are the most widely accepted recommendations
for weight gain during pregnancy. Weight gain above these values researchers have specified
will be considered as excessive weight gain for us.The levels of these molecules in the serum
of the study groups were measured using a commercial ELISA kit.
